Document Detail

Inefficiency as the major driver of excess costs in lung resection.
MedLine Citation:
PMID:  21955479     Owner:  NLM     Status:  Publisher    
BACKGROUND: Risk-adjusted outcomes of surgical care are important for quality and cost assessments. Although cardiac surgery is commonly studied, risk-adjusted analysis of excess costs of lung resection has not been pursued. METHODS: We used 2002 to 2005 National Inpatient Sample of the Healthcare Cost and Utilization Project data to evaluate adverse outcomes and costs in elective lung resections in hospitals with more than 20 cases during that period. Adverse outcomes were inpatient death or excessive risk-adjusted postoperative stay. Logistic models were defined to predict adverse outcomes. Linear models were designed to predict costs. Hospital-specific adverse outcome rates and costs were measured to define performance outliers. Cost-effective reference hospitals were used to define total excess costs. RESULTS: Among 12,182 patients at 215 hospitals undergoing lung resection, there were 336 inpatient deaths (2.8%) and 880 live discharges with prolonged risk-adjusted postoperative stay (7.2%). Predictive models for mortality and risk-adjusted postoperative stay had C statistics of 0.773 and 0.643, respectively. There were 11 ineffective hospitals (5.1%) with excessive adverse outcomes (P < .005) and 34 inefficient hospitals (15.8%) meeting quality measures but with higher than predicted costs (P < .0005). Ineffective hospitals had costs $1020 per case lower than predicted. Inefficient hospitals had costs $9978 higher than predicted. CONCLUSIONS: Inefficiency is the major factor in excess inpatient costs associated with lung resection in this model. Although refinements in databases, including total physician costs and postdischarge adverse event costs, will alter models, excess costs of lung resection appear to be driven by inefficiency, not adverse outcomes.
Donald E Fry; Michael Pine; Barbara L Jones; Roger J Meimban
Related Documents :
22038879 - Adverse outcomes associated with delayed intensive care unit transfers in an integrated...
21734199 - Hospitals respond to medicare payment shortfalls by both shifting costs and cutting the...
21752579 - Rehospitalizations, early revisions, infections, and hospital resource use in the first...
21632909 - How to manage type 2 diabetes in medical and surgical patients in the hospital.
22211429 - More patients are triaged using the emergency severity index than any other triage acui...
22042739 - Improving the discharge process by embedding a discharge facilitator in a resident team.
20503289 - Viruses and atypical bacteria associated with asthma exacerbations in hospitalized chil...
8377159 - Day hospital and home physiotherapy for stroke patients: a comparative cost-effectivene...
403199 - Evaluation of a simple device for bacteriological sampling of respirator-generated aero...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-26
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  -     ISSN:  1097-685X     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Michael Pine and Associates, Chicago, III; the Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, III; the Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preoperative left atrial dysfunction and risk of postoperative atrial fibrillation complicating thor...
Next Document:  Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of th...